COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
23 déc. 2024 07h45 HE
|
COSCIENS Biopharma Inc.
Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations...
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
12 nov. 2024 07h30 HE
|
COSCIENS Biopharma Inc.
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12,...
COSCIENS Biopharma Announces Change to Board of Directors
08 oct. 2024 07h30 HE
|
COSCIENS Biopharma Inc.
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
01 oct. 2024 17h30 HE
|
COSCIENS Biopharma Inc.
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
23 sept. 2024 07h30 HE
|
COSCIENS Biopharma Inc.
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27 août 2024 07h30 HE
|
COSCIENS Biopharma Inc.
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation -...
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
13 août 2024 08h05 HE
|
COSCIENS Biopharma Inc.
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
06 août 2024 18h00 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical...
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
16 juil. 2024 16h05 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
13 juin 2024 09h10 HE
|
Aeterna Zentaris Inc
Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or...